Mounjaro (Tirzepatide) Weight Loss Injections | Buy Online in the UK

Mounjaro is the brand name for tirzepatide, a prescription-only injection developed by Eli Lilly and licensed in the UK for chronic weight management in eligible adults.

Eli Lilly and Company is an American pharmaceutical company founded in 1876 and headquartered in Indianapolis. Lilly has been producing medicines for diabetes, cancer, mental health and, most recently, weight management for well over a century, and its treatments are now used by millions of people in more than 100 countries.

Tirzepatide first received regulatory approval in the United States in May 2022 for type 2 diabetes. It was licensed in the UK by the MHRA (Medicines and Healthcare products Regulatory Agency) in November 2023 specifically for weight management, and became available through UK pharmacies from early 2024.

It is supplied as a pre-filled KwikPen containing four weekly doses. Mounjaro acts on two naturally occurring incretin hormone pathways, GIP and GLP-1, helping regulate appetite, fullness, digestion and blood sugar.

What makes Mounjaro different from other weight loss injections?

Most weight loss injections you may have heard of including Wegovy and Saxenda, work on a single gut hormone receptor called GLP-1 (glucagon-like peptide-1). Mounjaro is different because it's what's known as a "dual agonist": it activates two receptors at once, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide).

This dual mechanism is the reason clinical trials have consistently shown Mounjaro producing some of the strongest average weight-loss results seen in this category of medicine to date, patients on the highest dose have lost more weight on average than those using single-receptor treatments in head-to-head trial data.

How is Mounjaro supplied?

Mounjaro comes as a pre-filled KwikPen, and in the UK is available in six dose strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg. Each pen is designed to deliver four weekly doses, so one pen lasts a full month of treatment. You don't need to draw up, measure, or mix anything yourself; the pen is built to make weekly dosing straightforward and consistent, whether you're self-injecting for the first time or you've been on treatment for months.

Is Mounjaro monitored for safety?

Yes. As a comparatively recently licensed medicine, Mounjaro carries what's known in the UK as black triangle (▼) status - this means it's under additional, close monitoring by the MHRA so that any new safety information is captured quickly as more people use it over the long term. This is standard practice for newly launched medicines generally, not a specific red flag unique to Mounjaro.

What is Mounjaro licensed for in the UK?

In the UK, Mounjaro is licensed for:

• Chronic weight management in adults with obesity, or who are overweight with a weight-related health condition
• Type 2 diabetes, where it helps lower blood sugar (HbA1c) alongside diet and exercise

This dual licensing is a point of difference from the US model - in the UK, one product (Mounjaro) legitimately covers both uses, prescribed according to your individual clinical need.

Unlike in the US where the diabetes version is called Mounjaro and a separate weight-loss version is sold under the name Zepbound - the UK only has one name and one product: Mounjaro. Zepbound is not a licensed or available brand in the UK, so anything you read about "Zepbound" is describing the exact same drug you'd get here as Mounjaro.

In the UK, Mounjaro must be prescribed after a clinical assessment. At Rightangled, a UK-registered clinician checks whether treatment is appropriate before a prescription is issued.

Mounjaro is made by Eli Lilly and Company, one of the world's largest pharmaceutical companies. Lilly is headquartered in Indianapolis, Indiana, in the United States, and has been developing medicines since 1876 making it well over 145 years old.

Lilly's treatments today reach patients in more than 100 countries, spanning diabetes care, cancer treatment, mental health, and, more recently, chronic weight management. Mounjaro (tirzepatide) was developed and launched by Lilly, first receiving regulatory approval in the United States in 2022.

What else has Eli Lilly made?

Lilly's history includes some of the most widely used medicines of the last century. It was the first company to mass-produce insulin in the 1920s, and has since developed treatments across diabetes, oncology, immunology and neuroscience.

Is Mounjaro genuine when bought through Rightangled?

Yes. Every Mounjaro pen supplied through Rightangled is sourced through the regulated UK pharmaceutical supply chain, dispensed by our GPhC-registered partner pharmacy. This means the medicine you receive is the same genuine, Lilly-manufactured product prescribed in any UK clinical setting never from an unregulated or unofficial source.

The core principle: a calorie deficit, made achievable

Weight loss, at its most basic biological level, requires burning more energy than you consume - a calorie deficit. The difficulty most people face isn't understanding this principle; it's sustaining it against constant hunger, cravings and the body's natural drive to defend its weight. Mounjaro works for weight loss by directly targeting the biological signals that make a calorie deficit so hard to maintain long-term.

The brain-gut feedback loop

Appetite isn't controlled by the stomach alone, it's a constant conversation between your gut, your pancreas and your brain. Tirzepatide, the active ingredient in Mounjaro, inserts itself into this conversation at multiple points simultaneously, which is a key reason its effect on weight is more pronounced than treatments working on a single pathway.

Why weight loss increases with dose

Mounjaro is started at a low dose (2.5mg) and increased gradually over months toward a maintenance dose, which may be anywhere from 5mg up to the maximum 15mg. Clinical trial data shows a clear dose-response relationship in general, higher maintenance doses are associated with greater average weight loss, which is why treatment plans are built around reaching an effective, well-tolerated dose over time rather than stopping at the starting dose.

Does Mounjaro work for weight loss without diabetes?

Yes. While tirzepatide's dual-hormone action also improves blood sugar control, its appetite and fullness effects work independently of whether someone has diabetes. This is why Mounjaro is licensed in the UK for weight management in adults with obesity, or who are overweight with a weight-related health condition, regardless of their diabetes status.

Does the weight loss stop once your body adjusts?

Some people notice their initial rate of weight loss slows after the first few months — this is a normal part of the process, often called a weight loss plateau, and reflects the body's metabolism adjusting to a lower weight rather than the medicine "wearing off." Continued treatment, alongside consistent diet and activity habits, typically supports further gradual progress rather than a sudden stop.

Why lifestyle changes still matter with Mounjaro

Mounjaro makes a calorie deficit far easier to sustain, it doesn't remove the need for one. Every major clinical trial of tirzepatide was conducted alongside dietary counselling and increased physical activity, and the strongest, most durable results are consistently seen in patients who combine treatment with sustainable lifestyle changes rather than relying on the injection in isolation.

Individual results vary. Dose, adherence, side effects, starting health, nutrition and activity all influence progress. Clinical trial averages do not guarantee an individual outcome.

A realistic timeline: appetite changes may occur early, while measurable weight change usually develops gradually over months as treatment and lifestyle changes continue.